{
  "claim_id": "claim_001",
  "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
  "document": "FlublokPI",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 5
  },
  "completeness_stats": {
    "existing_evidence": 4,
    "new_evidence_found": 5,
    "total_evidence": 6
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "For the 2024-2025 influenza season it is formulated to contain 135 mcg HA per 0.5 mL dose, with 45 mcg HA of each of the following 3 influenza virus strains: A/West Virginia 30 2022 (A/Wisconsin/67/2022 pdm 09 like virus) (H1 N1), A/Massachusetts/18/2022 (H3 N2) and B/Austria/1359417/2021.",
      "relevance_explanation": "This quote explicitly states the total and per-strain hemagglutinin (HA) content in Flublok, confirming it contains 135 mcg HA per dose (45 mcg per strain), which is three times the standard 15 mcg per strain in standard-dose flu vaccines."
    },
    {
      "id": 2,
      "quote": "Flublok contains recombinant HA proteins of the three strains of influenza virus specified by health authorities for inclusion in the annual seasonal vaccine. These proteins function as antigens which induce a humoral immune response, measured by hemagglutination inhibition (HI) antibodies.",
      "relevance_explanation": "This quote establishes that the HA proteins in Flublok are the immunogenic components responsible for inducing an immune response, directly linking HA content to immunogenicity."
    },
    {
      "id": 3,
      "quote": "5. Treanor JJ, Schiff GM, Hayden FG, et.al. Safety and immunogenicity of a baculovirus expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA. 2007 Vol. 297, pp. 1577-1582.",
      "relevance_explanation": "This reference, cited in the context of Flublok's clinical studies, directly addresses the immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine (Flublok), supporting the claim that its higher HA content is linked to greater immunogenicity."
    },
    {
      "id": 4,
      "quote": "2. Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and immunogenicity of Flublok trivalent recombinant baculovirus expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine. 2011, Vol. 29, pp. 2272-2278.",
      "relevance_explanation": "This reference is a clinical study specifically evaluating the immunogenicity of Flublok, supporting the claim that its higher HA content is associated with greater immunogenicity compared to standard-dose vaccines."
    },
    {
      "id": "comp_1",
      "quote": "Flublok is standardized according to United States Public Health Service (USPHS) requirements. For the 2024-2025 influenza season it is formulated to contain 135 mcg HA per 0.5 mL dose, with 45 mcg HA of each of the following 3 influenza virus strains: A/West Virginia 30 2022 (A/Wisconsin/67/2022 pdm 09 like virus) (H1 N1), A/Massachusetts/18/2022 (H3 N2) and B/Austria/1359417/2021.",
      "relevance_explanation": "This quote explicitly states the total hemagglutinin (HA) content per dose in Flublok, which is three times the standard 15 mcg per strain found in standard-dose flu vaccines, directly supporting the claim about antigen content.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "Across three clinical trials (Studies 2 - 4, Tables 2 and 3) a total of 2050 adults age 50 years and older received Flublok and 2048 received a U.S.-licensed trivalent inactivated influenza vaccine (IIV3) comparator.",
      "relevance_explanation": "This quote establishes that Flublok was directly compared to standard-dose flu vaccines (IIV3) in clinical trials, which is relevant for supporting claims about comparative immunogenicity.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}